BR112022021789A2 - Bibliotecas de ácido nucléico variantes para coronavírus - Google Patents

Bibliotecas de ácido nucléico variantes para coronavírus

Info

Publication number
BR112022021789A2
BR112022021789A2 BR112022021789A BR112022021789A BR112022021789A2 BR 112022021789 A2 BR112022021789 A2 BR 112022021789A2 BR 112022021789 A BR112022021789 A BR 112022021789A BR 112022021789 A BR112022021789 A BR 112022021789A BR 112022021789 A2 BR112022021789 A2 BR 112022021789A2
Authority
BR
Brazil
Prior art keywords
libraries
nucleic acid
acid libraries
variant nucleic
coronavirus variant
Prior art date
Application number
BR112022021789A
Other languages
English (en)
Inventor
Sato Aaron
Liu Qiang
Yuan Tom
Original Assignee
Twist Bioscience Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Twist Bioscience Corp filed Critical Twist Bioscience Corp
Publication of BR112022021789A2 publication Critical patent/BR112022021789A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/005—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies constructed by phage libraries
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1002—Coronaviridae
    • C07K16/1003—Severe acute respiratory syndrome coronavirus 2 [SARS‐CoV‐2 or Covid-19]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

BIBLIOTECAS DE ÁCIDO NUCLÉICO VARIANTES PARA CORONAVÍRUS. São fornecidos neste documento métodos e composições relacionados a bibliotecas de anticorpos otimizados com ácidos nucleicos que codificam para um anticorpo compreendendo sequências modificadas. As bibliotecas aqui descritas compreendem ácidos nucleicos que codificam anticorpos SARS-CoV-2 ou ACE2. Ainda aqui descritas são bibliotecas de proteínas geradas quando as bibliotecas de ácidos nucleicos são traduzidas. Ainda descritas neste documento são bibliotecas de células que expressam bibliotecas de ácidos nucleicos variegadas descritas neste documento.
BR112022021789A 2020-04-27 2021-04-27 Bibliotecas de ácido nucléico variantes para coronavírus BR112022021789A2 (pt)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202063016254P 2020-04-27 2020-04-27
US202063034896P 2020-06-04 2020-06-04
US202063069665P 2020-08-24 2020-08-24
US202063073362P 2020-09-01 2020-09-01
US202063104465P 2020-10-22 2020-10-22
US202063115568P 2020-11-18 2020-11-18
PCT/US2021/029485 WO2021222315A2 (en) 2020-04-27 2021-04-27 Variant nucleic acid libraries for coronavirus

Publications (1)

Publication Number Publication Date
BR112022021789A2 true BR112022021789A2 (pt) 2023-03-07

Family

ID=78374237

Family Applications (2)

Application Number Title Priority Date Filing Date
BR112022021780A BR112022021780A2 (pt) 2020-04-27 2021-04-27 Bibliotecas de ácido nucléico variantes para coronavírus
BR112022021789A BR112022021789A2 (pt) 2020-04-27 2021-04-27 Bibliotecas de ácido nucléico variantes para coronavírus

Family Applications Before (1)

Application Number Title Priority Date Filing Date
BR112022021780A BR112022021780A2 (pt) 2020-04-27 2021-04-27 Bibliotecas de ácido nucléico variantes para coronavírus

Country Status (11)

Country Link
US (2) US20210395344A1 (pt)
EP (2) EP4142739A2 (pt)
JP (2) JP2023523336A (pt)
KR (2) KR20230016184A (pt)
CN (2) CN116113420A (pt)
AU (2) AU2021263755A1 (pt)
BR (2) BR112022021780A2 (pt)
CA (2) CA3177030A1 (pt)
IL (2) IL297701A (pt)
MX (2) MX2022013513A (pt)
WO (2) WO2021222316A2 (pt)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2533173A (en) 2013-08-05 2016-06-15 Twist Bioscience Corp De Novo synthesized gene libraries
US10669304B2 (en) 2015-02-04 2020-06-02 Twist Bioscience Corporation Methods and devices for de novo oligonucleic acid assembly
US9981239B2 (en) 2015-04-21 2018-05-29 Twist Bioscience Corporation Devices and methods for oligonucleic acid library synthesis
IL258164B (en) 2015-09-18 2022-09-01 Twist Bioscience Corp Methods to regulate the activity of proteins and cells and a method for the production of nucleic acids
KR20180058772A (ko) 2015-09-22 2018-06-01 트위스트 바이오사이언스 코포레이션 핵산 합성을 위한 가요성 기판
JP6871364B2 (ja) 2016-09-21 2021-05-12 ツイスト バイオサイエンス コーポレーション 核酸に基づくデータ保存
CA3054303A1 (en) 2017-02-22 2018-08-30 Twist Bioscience Corporation Nucleic acid based data storage
AU2018284227B2 (en) 2017-06-12 2024-05-02 Twist Bioscience Corporation Methods for seamless nucleic acid assembly
EA202090562A1 (ru) 2017-09-11 2020-08-10 Твист Байосайенс Корпорейшн Связывающие gpcr белки и их синтез
US10894242B2 (en) 2017-10-20 2021-01-19 Twist Bioscience Corporation Heated nanowells for polynucleotide synthesis
SG11202011467RA (en) 2018-05-18 2020-12-30 Twist Bioscience Corp Polynucleotides, reagents, and methods for nucleic acid hybridization
SG11202109283UA (en) 2019-02-26 2021-09-29 Twist Bioscience Corp Variant nucleic acid libraries for antibody optimization
CN113766930A (zh) 2019-02-26 2021-12-07 特韦斯特生物科学公司 Glp1受体的变异核酸文库
AU2020298294A1 (en) 2019-06-21 2022-02-17 Twist Bioscience Corporation Barcode-based nucleic acid sequence assembly
MX2022013513A (es) * 2020-04-27 2023-01-16 Twist Bioscience Corp Bibliotecas de ácidos nucleicos variantes para coronavirus.
WO2022086866A1 (en) 2020-10-19 2022-04-28 Twist Bioscience Corporation Methods of synthesizing oligonucleotides using tethered nucleotides
WO2022204316A2 (en) * 2021-03-24 2022-09-29 Twist Bioscience Corporation Variant nucleic acid libraries for cd3
CA3238160A1 (en) * 2021-11-18 2023-05-25 Aaron Sato Dickkopf-1 variant antibodies and methods of use
WO2023102034A2 (en) * 2021-12-01 2023-06-08 Twist Bioscience Corporation Neuropilin-1 variant antibodies and methods of use
WO2023130123A2 (en) * 2022-01-03 2023-07-06 Twist Bioscience Corporation Bispecific sars-cov-2 antibodies and methods of use
WO2023235827A2 (en) * 2022-06-03 2023-12-07 The Rockefeller University Coronavirus-inhibiting antibodies

Family Cites Families (159)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6492107B1 (en) 1986-11-20 2002-12-10 Stuart Kauffman Process for obtaining DNA, RNA, peptides, polypeptides, or protein, by recombinant DNA technique
US5474796A (en) 1991-09-04 1995-12-12 Protogene Laboratories, Inc. Method and apparatus for conducting an array of chemical reactions on a support surface
ATE262374T1 (de) 1991-11-22 2004-04-15 Affymetrix Inc Kombinatorische strategien für polymersynthese
US5573905A (en) 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
US5368823A (en) 1993-02-11 1994-11-29 University Of Georgia Research Foundation, Inc. Automated synthesis of oligonucleotides
US7135312B2 (en) 1993-04-15 2006-11-14 University Of Rochester Circular DNA vectors for synthesis of RNA and DNA
US5455239A (en) 1993-08-05 1995-10-03 Merck & Co. Inc. 3-aryl of heteroaryl-7-heteroaralkylamido cephalosporin compounds, compositions and methods of use
US6893816B1 (en) 1993-10-28 2005-05-17 Houston Advanced Research Center Microfabricated, flowthrough porous apparatus for discrete detection of binding reactions
PT725682E (pt) 1993-10-28 2002-09-30 Houston Advanced Res Ct Dispositivo poroso microfabricado de escoamento
US6013440A (en) 1996-03-11 2000-01-11 Affymetrix, Inc. Nucleic acid affinity columns
AU6646398A (en) 1996-12-31 1998-07-31 Genometrix Incorporated Multiplexed molecular analysis apparatus and method
US6419883B1 (en) 1998-01-16 2002-07-16 University Of Washington Chemical synthesis using solvent microdroplets
US6028189A (en) 1997-03-20 2000-02-22 University Of Washington Solvent for oligonucleotide synthesis and methods of use
IL131978A0 (en) 1997-03-20 2001-03-19 Univ Washington Solvent for biopolymer synthesis solvent microdots and methods of use
EP0991930B1 (en) 1997-06-26 2004-06-16 Perseptive Biosystems, Inc. High density sample holder for analysis of biological samples
JP2002538790A (ja) 1999-03-08 2002-11-19 プロトジーン・ラボラトリーズ・インコーポレーテッド 長いｄｎａ配列を経済的に合成し、そして組み立てるための方法および組成物
US6472147B1 (en) 1999-05-25 2002-10-29 The Scripps Research Institute Methods for display of heterodimeric proteins on filamentous phage using pVII and pIX, compositions, vectors and combinatorial libraries
US20020025561A1 (en) 2000-04-17 2002-02-28 Hodgson Clague Pitman Vectors for gene-self-assembly
US7163660B2 (en) 2000-05-31 2007-01-16 Infineon Technologies Ag Arrangement for taking up liquid analytes
US6716629B2 (en) 2000-10-10 2004-04-06 Biotrove, Inc. Apparatus for assay, synthesis and storage, and methods of manufacture, use, and manipulation thereof
US6693187B1 (en) 2000-10-17 2004-02-17 Lievre Cornu Llc Phosphinoamidite carboxlates and analogs thereof in the synthesis of oligonucleotides having reduced internucleotide charge
US6905816B2 (en) 2000-11-27 2005-06-14 Intelligent Medical Devices, Inc. Clinically intelligent diagnostic devices and methods
US20020164824A1 (en) 2001-02-16 2002-11-07 Jianming Xiao Method and apparatus based on bundled capillaries for high throughput screening
US7211654B2 (en) 2001-03-14 2007-05-01 Regents Of The University Of Michigan Linkers and co-coupling agents for optimization of oligonucleotide synthesis and purification on solid supports
US20040161741A1 (en) 2001-06-30 2004-08-19 Elazar Rabani Novel compositions and processes for analyte detection, quantification and amplification
WO2003057924A1 (en) 2002-01-04 2003-07-17 Board Of Regents, The University Of Texas System Proofreading, error deletion, and ligation method for synthesis of high-fidelity polynucleotide sequences
US20070275411A1 (en) 2006-05-25 2007-11-29 Mcgall Glenn H Silane mixtures
US7563600B2 (en) 2002-09-12 2009-07-21 Combimatrix Corporation Microarray synthesis and assembly of gene-length polynucleotides
US20070059692A1 (en) 2002-10-28 2007-03-15 Xiaolian Gao Array oligomer synthesis and use
US7422911B2 (en) 2002-10-31 2008-09-09 Agilent Technologies, Inc. Composite flexible array substrate having flexible support
US7879580B2 (en) 2002-12-10 2011-02-01 Massachusetts Institute Of Technology Methods for high fidelity production of long nucleic acid molecules
US7932025B2 (en) 2002-12-10 2011-04-26 Massachusetts Institute Of Technology Methods for high fidelity production of long nucleic acid molecules with error control
WO2004058945A2 (en) 2002-12-23 2004-07-15 Agilent Technologies, Inc. Comparative genomic hybridization assays using immobilized oligonucleotide features and compositions for practicing the same
US7202264B2 (en) 2003-01-31 2007-04-10 Isis Pharmaceuticals, Inc. Supports for oligomer synthesis
JP2004268394A (ja) 2003-03-07 2004-09-30 Canon Inc インクジェット記録装置及びその制御方法
AU2004251256B2 (en) 2003-05-30 2009-05-28 The Board Of Trustees Of The University Of Illinois Gene expression profiles that identify genetically elite ungulate mammals
US8133670B2 (en) 2003-06-13 2012-03-13 Cold Spring Harbor Laboratory Method for making populations of defined nucleic acid molecules
CA2531684C (en) * 2003-07-22 2014-03-11 Crucell Holland B.V. Binding molecules against sars-coronavirus and uses thereof
WO2005060520A2 (en) 2003-11-25 2005-07-07 Dana-Farber Cancer Institute, Inc. ANTIBODIES AGAINST SARS-CoV AND METHODS OF USE THEREOF
PL1697507T3 (pl) 2003-12-02 2013-03-29 Pasteur Institut Zastosowanie białek i peptydów kodowanych przez genom nowego szczepu koronawirusa związanego z SARS
EP1733055A4 (en) 2004-02-27 2009-03-11 Harvard College polynucleotide
US8825411B2 (en) 2004-05-04 2014-09-02 Dna Twopointo, Inc. Design, synthesis and assembly of synthetic nucleic acids
JP2008525020A (ja) 2004-12-22 2008-07-17 ナショナル ユニバーシティ オブ シンガポール 新規ヘビ毒素
EP2361933A3 (en) * 2005-01-26 2012-05-02 Amgen Fremont Inc. Antibodies against interleukin-1 beta
US20070196834A1 (en) 2005-09-09 2007-08-23 Francesco Cerrina Method and system for the generation of large double stranded DNA fragments
CN101277758A (zh) 2005-09-14 2008-10-01 Illumina公司 连续聚合物合成器
EP1939621B1 (en) 2005-09-16 2014-11-19 Azbil Corporation Method for manufacturing substrate for biochip, and method for manufacturing biochip
EP4105644A3 (en) 2006-03-31 2022-12-28 Illumina, Inc. Systems and devices for sequence by synthesis analysis
EP2007907A2 (en) 2006-04-19 2008-12-31 Applera Corporation Reagents, methods, and libraries for gel-free bead-based sequencing
WO2008054543A2 (en) 2006-05-20 2008-05-08 Codon Devices, Inc. Oligonucleotides for multiplex nucleic acid assembly
DE102006039479A1 (de) 2006-08-23 2008-03-06 Febit Biotech Gmbh Programmierbare Oligonukleotidsynthese
EP2078077A2 (en) 2006-10-04 2009-07-15 Codon Devices, Inc Nucleic acid libraries and their design and assembly
US20080085511A1 (en) 2006-10-05 2008-04-10 Peck Bill J Preparation of biopolymer arrays
US20080085514A1 (en) 2006-10-10 2008-04-10 Peck Bill J Methods and devices for array synthesis
WO2008063135A1 (en) 2006-11-24 2008-05-29 Agency For Science, Technology And Research Apparatus for processing a sample in a liquid droplet and method of using the same
NO347649B1 (no) 2006-12-14 2024-02-12 Regeneron Pharma Humant antistoff eller antistoff fragment som spesifikt binder human deltaliknende ligand 4 (hDII4), nukleinsyremolekyl som koder for slike og vektor og vert-vektorsystemer, samt fremgangsmåte for fremstilling, sammensetning og anvendelse.
KR100827449B1 (ko) 2007-02-07 2008-05-07 삼성전자주식회사 광분해성 화합물과 상기 화합물이 커플링된 올리고머프로브 어레이용 기판, 올리고머 프로브 어레이 및 이의제조 방법
JP4582224B2 (ja) 2008-05-02 2010-11-17 ソニー株式会社 マイクロビーズ作製方法及びマイクロビーズ
JP4667490B2 (ja) 2008-07-09 2011-04-13 三菱電機株式会社 加熱調理器
US8808986B2 (en) 2008-08-27 2014-08-19 Gen9, Inc. Methods and devices for high fidelity polynucleotide synthesis
JP2012504416A (ja) 2008-09-30 2012-02-23 アボット・ラボラトリーズ 改良抗体ライブラリー
US20100301398A1 (en) 2009-05-29 2010-12-02 Ion Torrent Systems Incorporated Methods and apparatus for measuring analytes
WO2010053443A1 (en) 2008-11-06 2010-05-14 Agency For Science, Technology And Research Apparatus for biopolymer synthesis
JP2012508017A (ja) * 2008-11-07 2012-04-05 ファブラス エルエルシー 抗ｄｌｌ４抗体及びその使用
US20110286916A1 (en) 2008-11-20 2011-11-24 Jose Miguel Aste-Amezaga Generation and characterization of anti-notch antibodies for therapeutic and diagnostic use
US8637454B2 (en) 2009-01-06 2014-01-28 Dyax Corp. Treatment of mucositis with kallikrein inhibitors
EP2398915B1 (en) 2009-02-20 2016-08-24 Synthetic Genomics, Inc. Synthesis of sequence-verified nucleic acids
WO2010115122A2 (en) 2009-04-03 2010-10-07 Illumina, Inc. Generation of uniform fragments of nucleic acids using patterned substrates
EP3279215B1 (en) 2009-11-24 2020-02-12 MedImmune Limited Targeted binding agents against b7-h1
US8716467B2 (en) 2010-03-03 2014-05-06 Gen9, Inc. Methods and devices for nucleic acid synthesis
WO2011109031A1 (en) 2010-03-05 2011-09-09 Synthetic Genomics, Inc. Methods for cloning and manipulating genomes
WO2012033987A2 (en) 2010-09-09 2012-03-15 Purdue Research Foundation Anti-human folate receptor beta antibodies and methods of use
US20140045728A1 (en) 2010-10-22 2014-02-13 President And Fellows Of Harvard College Orthogonal Amplification and Assembly of Nucleic Acid Sequences
JP6118725B2 (ja) 2010-11-12 2017-04-19 ジェン９・インコーポレイテッドＧｅｎ９，ＩＮＣ． 核酸合成のための方法およびデバイス
US9487807B2 (en) 2010-12-27 2016-11-08 Ibis Biosciences, Inc. Compositions and methods for producing single-stranded circular DNA
CN103597068A (zh) 2011-03-30 2014-02-19 独立行政法人国立长寿医疗研究中心 膜分选培养器、膜分选培养试剂盒、和使用其的干细胞分选方法、以及分离膜
ES2844529T3 (es) 2011-09-01 2021-07-22 Genome Compiler Corp Sistema de diseño, visualización y transacciones de construcciones polinucleotídicas para fabricar las mismas
US8840981B2 (en) 2011-09-09 2014-09-23 Eastman Kodak Company Microfluidic device with multilayer coating
WO2013049227A2 (en) 2011-09-26 2013-04-04 Geneart Ag High efficiency, small volume nucleic acid synthesis
US8987174B2 (en) 2011-10-28 2015-03-24 Prognosys Biosciences, Inc. Methods for manufacturing molecular arrays
WO2013096692A1 (en) 2011-12-21 2013-06-27 Illumina, Inc. Apparatus and methods for kinetic analysis and determination of nucleic acid sequences
AU2013229488B2 (en) 2012-03-08 2017-12-07 Janssen Vaccines & Prevention B.V. Human binding molecules capable of binding to and neutralizing influenza B viruses and uses thereof
SI2852615T1 (sl) 2012-05-22 2019-02-28 Bristol-Myers Squibb Company IL-17A/F IL-23 bispecifična protitelesa in njihova uporaba
WO2014021938A1 (en) 2012-08-02 2014-02-06 The Board Of Trustees Of The Leland Stanford Junior University Methods and apparatus for nucleic acid synthesis using oligo-templated polymerization
KR20140048733A (ko) 2012-10-16 2014-04-24 삼성전자주식회사 다중 웰 플레이트 및 상기 다중 웰 플레이트를 이용한 표적 물질 분석 방법
GB2533173A (en) 2013-08-05 2016-06-15 Twist Bioscience Corp De Novo synthesized gene libraries
US20150145336A1 (en) 2013-11-27 2015-05-28 Solantro Semiconductor Corp. Modular power conversion system and method
WO2016022557A1 (en) 2014-08-05 2016-02-11 Twist Bioscience Corporation Cell free cloning of nucleic acids
EP3191604B1 (en) 2014-09-09 2021-04-14 Igenomx International Genomics Corporation Methods and compositions for rapid nucleic acid library preparation
JP6859259B2 (ja) 2014-11-19 2021-04-14 ジェネンテック， インコーポレイテッド ＢＡＣＥｌに対する抗体及び神経疾患免疫療法のためのその使用
TWI702229B (zh) 2014-12-19 2020-08-21 美商再生元醫藥公司 流行性感冒病毒血球凝集素之人類抗體
AU2016206457B2 (en) 2015-01-16 2021-11-11 Juno Therapeutics, Inc. Antibodies and chimeric antigen receptors specific for ROR1
WO2016126987A1 (en) 2015-02-04 2016-08-11 Twist Bioscience Corporation Compositions and methods for synthetic gene assembly
US10669304B2 (en) 2015-02-04 2020-06-02 Twist Bioscience Corporation Methods and devices for de novo oligonucleic acid assembly
US9981239B2 (en) 2015-04-21 2018-05-29 Twist Bioscience Corporation Devices and methods for oligonucleic acid library synthesis
US20160333340A1 (en) 2015-05-11 2016-11-17 Twist Bioscience Corporation Compositions and methods for nucleic acid amplification
IL258164B (en) 2015-09-18 2022-09-01 Twist Bioscience Corp Methods to regulate the activity of proteins and cells and a method for the production of nucleic acids
KR20180058772A (ko) 2015-09-22 2018-06-01 트위스트 바이오사이언스 코포레이션 핵산 합성을 위한 가요성 기판
CA2997444A1 (en) 2015-09-29 2017-04-06 Amgen Inc. Asgr inhibitors for reducing cholesterol levels
MA43053A (fr) 2015-09-30 2018-08-08 Janssen Biotech Inc Anticorps antagonistes se liant spécifiquement au cd40 humain et procédés d'utilisation
CN108603307A (zh) 2015-12-01 2018-09-28 特韦斯特生物科学公司 功能化表面及其制备
US20170357752A1 (en) 2016-06-10 2017-12-14 Twist Bioscience Corporation Systems and methods for automated annotation and screening of biological sequences
WO2018026920A1 (en) 2016-08-03 2018-02-08 Twist Bioscience Corporation Textured surfaces for polynucleotide synthesis
JP6854340B2 (ja) 2016-08-22 2021-04-07 ツイスト バイオサイエンス コーポレーション デノボ合成された核酸ライブラリ
JP6871364B2 (ja) 2016-09-21 2021-05-12 ツイスト バイオサイエンス コーポレーション 核酸に基づくデータ保存
WO2018094263A1 (en) 2016-11-18 2018-05-24 Twist Bioscience Corporation Polynucleotide libraries having controlled stoichiometry and synthesis thereof
US10907274B2 (en) 2016-12-16 2021-02-02 Twist Bioscience Corporation Variant libraries of the immunological synapse and synthesis thereof
EP3565839A4 (en) * 2017-01-05 2021-04-21 Gensun Biopharma Inc. CHECKPOINT REGULATOR ANTAGONISTS
MX2019008197A (es) 2017-01-06 2019-09-11 Scholar Rock Inc Inhibidores de tgfb1 permisivos del contexto, espicificos de isoformas y uso de los mismos.
CA3054303A1 (en) 2017-02-22 2018-08-30 Twist Bioscience Corporation Nucleic acid based data storage
AU2018234624B2 (en) 2017-03-15 2023-11-16 Twist Bioscience Corporation De novo synthesized combinatorial nucleic acid libraries
CN110913865A (zh) 2017-03-15 2020-03-24 特韦斯特生物科学公司 免疫突触的变体文库及其合成
SG10201912494TA (en) * 2017-05-08 2020-02-27 Adimab Llc Anti-cd3-binding domains and antibodies comprising them, and methods for their generation and use
WO2018231864A1 (en) 2017-06-12 2018-12-20 Twist Bioscience Corporation Methods for seamless nucleic acid assembly
AU2018284227B2 (en) 2017-06-12 2024-05-02 Twist Bioscience Corporation Methods for seamless nucleic acid assembly
GB201709808D0 (en) 2017-06-20 2017-08-02 Kymab Ltd Antibodies
EA202090562A1 (ru) 2017-09-11 2020-08-10 Твист Байосайенс Корпорейшн Связывающие gpcr белки и их синтез
US10111883B1 (en) 2017-09-18 2018-10-30 Bellus Health Cough Inc. Selective P2X3 modulators
US10894242B2 (en) 2017-10-20 2021-01-19 Twist Bioscience Corporation Heated nanowells for polynucleotide synthesis
WO2019084500A1 (en) 2017-10-27 2019-05-02 Twist Bioscience Corporation SYSTEMS AND METHODS FOR CLASSIFYING POLYNUCLEOTIDES
EP3735459A4 (en) 2018-01-04 2021-10-06 Twist Bioscience Corporation DNA-BASED DIGITAL INFORMATION STORAGE
SG11202011467RA (en) 2018-05-18 2020-12-30 Twist Bioscience Corp Polynucleotides, reagents, and methods for nucleic acid hybridization
US10969965B2 (en) 2018-12-24 2021-04-06 Western Digital Technologies, Inc. Dynamic performance density tuning for data storage device
CA3124980A1 (en) 2018-12-26 2020-07-02 Twist Bioscience Corporation Highly accurate de novo polynucleotide synthesis
JP2022521766A (ja) 2019-02-25 2022-04-12 ツイスト バイオサイエンス コーポレーション 次世代シーケンシングのための組成物および方法
SG11202109283UA (en) 2019-02-26 2021-09-29 Twist Bioscience Corp Variant nucleic acid libraries for antibody optimization
CN113766930A (zh) 2019-02-26 2021-12-07 特韦斯特生物科学公司 Glp1受体的变异核酸文库
AU2020298294A1 (en) 2019-06-21 2022-02-17 Twist Bioscience Corporation Barcode-based nucleic acid sequence assembly
US20220243195A1 (en) 2019-06-21 2022-08-04 Twist Bioscience Corporation Barcode-based nucleic acid sequence assembly
CA3148245A1 (en) 2019-07-22 2021-01-28 Igenomx International Genomics Corporation Methods and compositions for high throughput sample preparation using double unique dual indexing
KR20220069046A (ko) 2019-09-23 2022-05-26 트위스트 바이오사이언스 코포레이션 단일 도메인 항체에 대한 변이체 핵산 라이브러리
KR20220066151A (ko) 2019-09-23 2022-05-23 트위스트 바이오사이언스 코포레이션 Crth2에 대한 변이체 핵산 라이브러리
EP4073296A4 (en) 2019-12-09 2024-05-22 Twist Bioscience Corporation NUCLEIC ACID VARIANT LIBRARIES FOR ADENOSINE RECEPTORS
AU2021220847A1 (en) 2020-02-11 2022-09-01 Vanderbilt University Human monoclonal antibodies to severe acute respiratory syndrome coronavirus 2 (SARS-CoV- 2)
CN111592594B (zh) 2020-03-13 2022-05-10 北京大学 一种抗新型冠状病毒的单克隆抗体及其应用
WO2021195326A1 (en) 2020-03-26 2021-09-30 Vanderbilt University Human monoclonal antibodies to severe acute respiratory syndrome coronavirus 2 (sars-cov-2)
WO2021195385A1 (en) 2020-03-26 2021-09-30 Vanderbilt University HUMAN MONOCLONAL ANTIBODIES TO SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-GoV-2)
CR20220545A (es) 2020-03-26 2023-01-09 Univ Vanderbilt ANTICUERPOS MONOCLONALES HUMANOS DIRIGIDOS CONTRA EL CORONAVIRUS 2 DEL SÍNDROME RESPIRATORIO AGUDO GRAVE (SARS-CoV-2)
US20230122364A1 (en) 2020-03-27 2023-04-20 Vanderbilt University HUMAN MONOCLONAL ANTIBODIES TO SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-CoV-2)
CN115916496A (zh) 2020-04-14 2023-04-04 奥西利姆生物技术公司 通过数字光刻***和方法的动态微加工
MX2022013513A (es) * 2020-04-27 2023-01-16 Twist Bioscience Corp Bibliotecas de ácidos nucleicos variantes para coronavirus.
WO2022010934A2 (en) 2020-07-07 2022-01-13 Twist Bioscience Corporation Devices and methods for light-directed polymer synthesis
US20220106586A1 (en) 2020-08-25 2022-04-07 Twist Bioscience Corporation Compositions and methods for library sequencing
US20220064313A1 (en) 2020-08-26 2022-03-03 Twist Bioscience Corporation Methods and compositions relating to glp1r variants
WO2022047076A1 (en) 2020-08-28 2022-03-03 Twist Bioscience Corporation Devices and methods for synthesis
EP4225912A1 (en) 2020-10-05 2023-08-16 Twist Bioscience Corporation Hybridization methods and reagents
WO2022086866A1 (en) 2020-10-19 2022-04-28 Twist Bioscience Corporation Methods of synthesizing oligonucleotides using tethered nucleotides
WO2022087293A1 (en) 2020-10-22 2022-04-28 Twist Bioscience Corporation Methods and systems for detecting coronavirus
US20220135965A1 (en) 2020-10-26 2022-05-05 Twist Bioscience Corporation Libraries for next generation sequencing
WO2022098662A2 (en) 2020-11-03 2022-05-12 Twist Bioscience Corporation Methods and compositions relating to chemokine receptor variants
EP4281112A1 (en) 2021-01-21 2023-11-29 Twist Bioscience Corporation Methods and compositions relating to adenosine receptors
US20220277808A1 (en) 2021-02-19 2022-09-01 Twist Bioscience Corporation Libraries for identification of genomic variants
EP4314074A1 (en) 2021-03-24 2024-02-07 Twist Bioscience Corporation Variant nucleic acid libraries for tigit
WO2022204316A2 (en) 2021-03-24 2022-09-29 Twist Bioscience Corporation Variant nucleic acid libraries for cd3
US20220323924A1 (en) 2021-03-24 2022-10-13 Twist Bioscience Corporation Electrochemical polynucleotide synthesis
US20220356463A1 (en) 2021-04-09 2022-11-10 Twist Bioscience Corporation Libraries for mutational analysis
US20220356468A1 (en) 2021-05-03 2022-11-10 Twist Bioscience Corporation Variant nucleic acid libraries for ion channels
EP4334515A1 (en) 2021-05-03 2024-03-13 Twist Bioscience Corporation Variant nucleic acid libraries for glycans
WO2022271884A2 (en) 2021-06-22 2022-12-29 Twist Bioscience Corporation Methods and compositions relating to covid antibody epitopes

Also Published As

Publication number Publication date
CN116113420A (zh) 2023-05-12
US20210355194A1 (en) 2021-11-18
CA3177030A1 (en) 2021-11-04
EP4142784A2 (en) 2023-03-08
US20210395344A1 (en) 2021-12-23
JP2023523335A (ja) 2023-06-02
MX2022013513A (es) 2023-01-16
JP2023523336A (ja) 2023-06-02
WO2021222316A3 (en) 2021-12-09
CA3177029A1 (en) 2021-11-04
AU2021263756A1 (en) 2022-12-15
MX2022013499A (es) 2023-01-16
BR112022021780A2 (pt) 2023-03-07
CN116209463A (zh) 2023-06-02
KR20230016184A (ko) 2023-02-01
US12018065B2 (en) 2024-06-25
IL297700A (en) 2022-12-01
EP4142739A2 (en) 2023-03-08
IL297701A (en) 2022-12-01
WO2021222315A3 (en) 2021-12-09
WO2021222316A2 (en) 2021-11-04
KR20230017781A (ko) 2023-02-06
WO2021222315A2 (en) 2021-11-04
AU2021263755A1 (en) 2022-12-15

Similar Documents

Publication Publication Date Title
BR112022021789A2 (pt) Bibliotecas de ácido nucléico variantes para coronavírus
WO2022271884A3 (en) Methods and compositions relating to covid antibody epitopes
WO2023023190A3 (en) Single domain antibodies for sars-cov-2
WO2023023183A3 (en) Sars-cov-2 antibodies and related compositions and methods of use
EA201990861A1 (ru) Рнк-направляемые модифицирующие нуклеиновые кислоты ферменты и способы их применения
BR112022011235A2 (pt) Bibliotecas de variantes de ácido nucleico para receptores de adenosina
BR112015000836A2 (pt) método para identificar um polipeptídeo tendo uma funcionalidade ou especificidade de ligação desejadas, biblioteca de moléculas de polinucleotídeo, método para gerar uma biblioteca de polinucleotídeos, vetor, célula hospedeira, anticorpo e método para gerar uma população de células hospedeiras
UY35286A (es) Construcciones de anticuerpos para CDH19 y CD3
BR112019005316A2 (pt) anticorpos monoclonais para morte programada 1 (pd-1)
CR9969A (es) Anticuerpos anti-globulomero ab, porciones de union a antigeno de estos, hibridomas correspondientes, acidos nucleicos, vectores, celulas huesped, metodos para producir dichos anticuerpos, composiciones que comprenden dichos anticuerpos
SV2006002513A (es) Anticuerpos anti-il-6, composiciones, metodos y usos ref. docket cen5094svnp
CL2009000082A1 (es) Acido nucleico que codifica anticuerpos anti cd79a o anti cd79b para el tratamiento de tumores hematopoyeticos; vector y células huésped que los comprenden; polipeptido codificado por dicho acido nucleico, inmunoconjugado con el cuerpo.
CL2011000308A1 (es) Anticuerpo monoclonal que se une al gen 3 de la activacion linfocitaria (lag-3) humana; composicion que comprende dicho anticuerpo; molecula de acido nucleico que lo codifica; vector de expresion y celula huesped que lo comprende; metodo de preparacion; y su uso para estimular la respuesta inmune.
PE20130205A1 (es) Proteinas de union a il-1
BRPI0812091A2 (pt) Método para fabricar uma proteína policlonal recombinante
CY1109230T1 (el) Ισομεραση συζευγμενου λινελαϊκου οξεος και μια διαδικασια για την παρασκευη συζευγμενου λινελαϊκου οξεος
CL2011002611A1 (es) Anticuerpo aislado anti-cadherina-17; molecula de acido nucleico que lo codifica; vector; celula huesped; metodo de produccion; inmunoconjugado que lo comprende; composicion que lo comprende; y su uso para tratar o prevenir una enfermedad asociada con celulas objetivo que expresan cadherina-17.
BR112022022503A2 (pt) Anticorpos neutralizantes que se ligam à proteína s de sars-cov-2
MX2019009045A (es) Nuevas luciferasas y metodos para su uso.
AR103794A1 (es) Producción de alquenos
BR112021019701A2 (pt) Anticorpos multiespecíficos para antígeno de câncer de bomba de efluxo e composições, reagentes, kits e métodos relacionados aos mesmos
Gupta et al. Mapping of post-translational modifications of transition proteins, TP1 and TP2, and identification of protein arginine methyltransferase 4 and lysine methyltransferase 7 as methyltransferase for TP2
BR112022008075A2 (pt) Métodos de seqüênciamento de proteínas de célula única e de ácido nucleico
EA202190892A1 (ru) Клеточные анализы клостридиальных нейротоксинов
AR070146A1 (es) Gen de bacillus thuringiensis (bt) con actividad contra coleopteros

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 3A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2775 DE 12-03-2024 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.